
5.90.012

Section:	Prescription Drugs	Effective Date:	April 1, 2025
Subsection:	Topical Products	Original Policy Date:	May 29, 2015
Subject:	Ecoza	Page:	1 of 4

Last Review Date: March 7, 2025

Ecoza

Description

Ecoza (econazole)

Background

Ecoza topical foam is a prescription medicine used on the skin to treat athlete's foot that is between the toes (interdigital tinea pedis) caused by the organisms *Trichophyton rubrum*, *Trichophyton mentagrophytes* and *Epidermophyton floccosum* in patients 12 years of age and older (1).

Regulatory Status

FDA-approved indications: Ecoza is indicated for the treatment of interdigital tinea pedis caused by *Trichophyton rubrum*, *Trichophyton mentagrophytes*, and *Epidermophyton floccosum* in patients 12 years of age and older (1).

Safety and effectiveness of Ecoza in pediatric patients under 12 years of age has not been established (1).

Related policies

Ertaczo, Exelderm, Jublia, Kerydin, Luzu, Oxistat

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Ecoza may be considered **medically necessary** if the conditions indicated below are met.

Ecoza may be considered **investigational** for all other indications.

Section:	Prescription Drugs	Effective Date:	April 1, 2025
Subsection:	Topical Products	Original Policy Date:	May 29, 2015
Subject:	Ecoza	Page:	2 of 4

Prior-Approval Requirements

Age 12 years of age or older

Diagnosis

Patient must have the following:

1. Interdigital Tinea Pedis

AND ALL of the following:

1. Suspected infection of **ONE** of the following fungal species
 - a. *Trichophyton rubrum*
 - b. *Trichophyton mentagrophytes*
 - c. *Epidermophyton floccosum*
2. Inadequate treatment response, intolerance, or contraindication to a topical or oral antifungal legend medication (e.g., fluconazole, terbinafine, ketoconazole, etc.)

Prior – Approval *Renewal* Requirements

Age 12 years of age or older

Diagnosis

Patient must have the following:

1. Interdigital Tinea Pedis

AND ALL of the following:

1. Suspected infection of **ONE** of the following fungal species
 - a. *Trichophyton rubrum*
 - b. *Trichophyton mentagrophytes*
 - c. *Epidermophyton floccosum*

[Policy Guidelines](#)

Pre - PA Allowance

None

Section:	Prescription Drugs	Effective Date:	April 1, 2025
Subsection:	Topical Products	Original Policy Date:	May 29, 2015
Subject:	Ecoza	Page:	3 of 4

Prior - Approval Limits

Duration 1 month

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Ecoza is antifungal cream used topically to treat interdigital tinea pedis caused by the organisms *Trichophyton rubrum*, *Trichophyton mentagrophytes* and *Epidermophyton floccosum*. Safety and effectiveness of Ecoza in pediatric patients under the age of 12 has not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Ecoza while maintaining optimal therapeutic outcomes.

References

1. Ecoza [package Insert]. Mahwah, NJ: Glenmark Therapeutics Inc.; March 2019.

Policy History

<i>Date</i>	<i>Action</i>
June 2015	Addition to PA
December 2016	Annual editorial review and reference update Addition of age to the renewal section Policy number change from 5.14.12 to 5.90.12
September 2017	Annual review
September 2018	Annual review
September 2019	Annual review
September 2020	Annual review
March 2021	Annual review and reference update
March 2022	Annual review
March 2023	Annual review. Changed policy number to 5.90.012
September 2023	Annual review. Per SME, revised requirement for laboratory documentation of a fungal infection to “suspected infection”, added examples of legend drugs, removed requirement for continuation: “NOT used in a previously treated location within the last 12 months”
March 2024	Annual review
March 2025	Annual review

Keywords

5.90.012

Section:	Prescription Drugs	Effective Date:	April 1, 2025
Subsection:	Topical Products	Original Policy Date:	May 29, 2015
Subject:	Ecoza	Page:	4 of 4

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 7, 2025 and is effective on April 1, 2025.